Special Issue "Automated Technology for Personalized Cancer Medicine: A Theme Issue in Honor of Prof. Dr. Thomas Grogan"

A special issue of Hemato (ISSN 2673-6357).

Deadline for manuscript submissions: closed (31 March 2021).

Special Issue Editors

Prof. Dr. Teresa Marafioti
E-Mail Website
Guest Editor
Department of Cellular Pathology, University College London, 21 University Street, London WC1E 6DE, UK
Interests: microscope-based techniques; immunohistochemistry; immunofluorescence; antibodies; biomarkers; hematological malignancies; solid tumors; immuno-oncopathology; tumor microenvironment; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Annunziata Gloghini
E-Mail Website
Guest Editor
Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Via G. Venezian 1, I-20133 Milano, Italy
Interests: immunohistochemistry; in situ molecular techniques; brightfield in situ hybridization; virologic characterization; EBV; HHV8/KSHV; HPV; tumor microenvironment; Hodgkin’s lymphoma; HIV-associated lymphomas
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This honorary issue celebrates Prof. Thomas Grogan, Emeritus Professor of Pathology at the University of Arizona and founder of Ventana Medical Systems Inc.

Prof Grogan’s scientific work was of great relevance in actively contributing to the development of the WHO classification of tumours of the hemopoietic and lymphoma tissues and his innovations in automated immunohistochemistry technology, as well as pre-analytical tissue processing, allowed him to develop several patents. The impact of these methodologies showed the clinical importance of cancer pathology, as they ensure reliable test results for determining patients’ treatment options. These advances, recognised by pathologists and clinical oncologists, further contributed to elevating the scientific importance of pathology.

We dedicate this honorary Special Issue to Prof. Tom Grogan, entitled "Automated Technology for Personalized Cancer Medicine", highlighting his major professional contributions, including novel development in the fields of immunohistology, in situ hybridization and clinical biomarkers.

The Special Issue will also focus on the impact of automated technologies on diagnostic and molecular pathology, as well as the identification of novel cancer therapies.

Prof. Dr. Teresa Marafioti
Prof. Dr. Annunziata Gloghini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized cancer medicine
  • cancer diagnosis
  • automated technology
  • lymphoma classification

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

Review
Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy
Hemato 2021, 2(2), 281-304; https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2020017 - 14 May 2021
Viewed by 506
Abstract
Diffuse large B-cell lymphomas (DLBCL)s, the most common type of Non-Hodgkin’s Lymphoma, constitute a heterogeneous group of disorders including different disease sites, strikingly diverse molecular features and a profound variability in the clinical behavior. Molecular studies and clinical trials have partially revealed the [...] Read more.
Diffuse large B-cell lymphomas (DLBCL)s, the most common type of Non-Hodgkin’s Lymphoma, constitute a heterogeneous group of disorders including different disease sites, strikingly diverse molecular features and a profound variability in the clinical behavior. Molecular studies and clinical trials have partially revealed the underlying causes for this variability and have made possible the recognition of some molecular variants susceptible of specific therapeutic approaches. The main histogenetic groups include the germinal center, activated B cells, thymic B cells and terminally differentiated B cells, a basic scheme where the large majority of DLBCL cases can be ascribed. The nodal/extranodal origin, specific mutational changes and microenvironment peculiarities provide additional layers of complexity. Here, we summarize the status of the knowledge and make some specific proposals for addressing the future development of targeted therapy for DLBC cases. Full article
Show Figures

Graphical abstract

Other

Jump to: Review

Commentary
On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology
Hemato 2021, 2(1), 103-115; https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010006 - 28 Feb 2021
Viewed by 457
Abstract
The story of Thomas Grogan, MD is one of the most compelling narratives in the modern history of pathology. Progressing from a quintessential academic pathologist to an entrepreneur and a renowned inventor, his remarkable journey is one of creativity, courage, and a keen [...] Read more.
The story of Thomas Grogan, MD is one of the most compelling narratives in the modern history of pathology. Progressing from a quintessential academic pathologist to an entrepreneur and a renowned inventor, his remarkable journey is one of creativity, courage, and a keen focus on improving the care of cancer patients. By enabling precision health and empowering the pathologist in that mission, he transformed the landscape of diagnostic pathology. In this review, we describe some of his salient contributions and how his vision has shaped and continues to shape hematopathology today. Full article
Show Figures

Figure 1

Back to TopTop